Welcome to our dedicated page for Revive Therapeutics news (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on Revive Therapeutics stock.
Revive Therapeutics Ltd. (RVVTF) is a specialty life sciences company whose news flow centers on the development of therapeutics for infectious diseases and medical countermeasures. Company updates frequently highlight progress with Bucillamine, a thiol-based drug under investigation for nerve agent exposure, long COVID, and other potential indications related to brain injury and viral infections.
Many recent announcements focus on Revive’s collaboration with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence. These releases describe the design and status of a research study evaluating Bucillamine as a potential treatment for nerve agent–induced brain injury, including timelines for study completion and the conditions under which results may be released. Technical details, such as work on GABA(A) receptor neuroprotection and comparisons with antioxidant compounds like n-acetylcysteine, are also featured.
Investors and observers can also find news on Revive’s broader Bucillamine strategy, including development of a next-generation lyophilized formulation in collaboration with the University of Waterloo, and references to FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation. Additional items may cover exploratory opportunities in traumatic brain injury, viral infections, and potential applications in solid tumor treatment.
Another recurring theme in Revive’s news is corporate finance activity. Press releases outline private placement offerings, unit and warrant structures, and the use of proceeds for working capital and trade payables, as well as debt settlements through equity issuance. For readers tracking RVVTF, the news page provides a consolidated view of scientific collaborations, pipeline developments, and financing decisions that shape the company’s therapeutic programs.
Revive Therapeutics (OTCQB: RVVTF; CSE: RVV) provided an update on its collaborative research study with Defence R&D Canada – Suffield Research Centre (DRDC) evaluating Bucillamine as a potential treatment for nerve agent–induced brain injury. The company said the DRDC-led study is expected to conclude with results in January 2026. Any findings will be released only with the express authorization of DRDC. Revive indicated it will continue to provide updates as the study advances toward completion.
Revive Therapeutics (OTCQB: RVVTF) provided an update on an ongoing research study evaluating bucillamine as a potential treatment for nerve agent–induced brain injury.
The study is conducted in collaboration with Defence R&D Canada – Suffield Research Centre (DRDC), which is evaluating pharmacological compounds that may mitigate nerve agent effects. The study remains in progress and final findings will be released only with DRDC authorization. Revive said it will provide further updates as the study advances toward completion.
Revive Therapeutics (OTCQB: RVVTF), a specialty life sciences company, has completed the second tranche of its private placement by issuing 4,352,381 units at $0.021 per unit, raising gross proceeds of $91,400.
Each unit consists of one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables settlement. Securities issued are subject to a four-month hold period ending January 19, 2026.
Revive Therapeutics (OTCQB: RVVTF) has announced an extension of its private placement offering. The company aims to raise up to $650,000 through the issuance of up to 30,952,381 units at $0.021 per unit. Each unit includes one common share and one warrant exercisable at $0.05 for 36 months.
The company has already completed a first tranche in August 2025, raising $60,900 through 2,900,000 units, leaving $589,000 worth of units available. The proceeds will be used for working capital and trade payables settlement. The securities will have a four-month and one-day hold period from issuance.
Revive Therapeutics (OTCQB: RVVTF) has completed the first tranche of its private placement offering, raising $60,900 through the issuance of 2.9 million units at $0.021 per unit. Additionally, the company settled $67,400 in debt through the issuance of 3.2 million units at the same price.
Each unit consists of one common share and one warrant exercisable at $0.05 for 36 months. The company also issued 100,000 compensation options to an investment dealer. The proceeds will be used for working capital and trade payables, with securities subject to a hold period until December 9, 2025.
Revive Therapeutics (OTCQB: RVVTF) has announced a proposed private placement offering of up to 30,952,381 units at $0.021 per unit, aiming to raise gross proceeds of up to $650,000. Additionally, the company plans to settle a $67,400 debt through the issuance of 3,209,523 units at the same price.
Each unit includes one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables. The offering may close in multiple tranches, with securities subject to a four-month hold period.
Revive Therapeutics (OTCQB: RVVTF) has issued a clarification regarding its ongoing research study of Bucillamine as a potential nerve agent countermeasure. The study, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC), is investigating compounds that could mitigate nerve agent-induced brain injury.
The research is scheduled to continue through September 2025. Results will only be released with DRDC's explicit authorization. The company emphasized that any future research collaborations with DRDC would only be considered after the current study's completion and dependent on satisfactory results.
Revive Therapeutics (OTCQB: RVVTF) is nearing completion of a crucial study evaluating Bucillamine as a nerve agent countermeasure in partnership with Defence R&D Canada (DRDC). The study is set to conclude by September 2025, with potential Health Canada approval for strategic stockpiling by 2026.
Bucillamine, a thiol-based drug with proven safety profile, works by replenishing glutathione to protect the brain and organs from toxic exposures. The company aims to expand its applications to include traumatic brain injury (TBI) and viral infections. The successful development could position Revive for significant government stockpiling contracts with Canada and its "Five Eyes" intelligence partners.
Revive Therapeutics (RVVTF) has provided an update on its research study of Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC). The study is scheduled to conclude by June 2025, focusing on GABA receptor antibodies and data confirmation. Positive results could lead to human clinical trials in the second half of 2025, seeking FDA and Health Canada approvals for nerve agent and organophosphate pesticide poisoning treatment.
Bucillamine, which is a more potent antioxidant than n-acetylcysteine (NAC), shows potential in protecting GABA(A) receptors and improving anticonvulsant therapies' effectiveness while reducing bleeding risks associated with NAC. The research also explores Bucillamine's applications in traumatic brain injury and viral infections.